Product Description: FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer[1][2][3][4].
Applications: Cancer-programmed cell death
Formula: C25H25N5O4S3
References: [1]Seedor, R. et al., (2021). Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers, 13(21), 5503. /[2]Gang Fu, et al., SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion, Pathology - Research and Practice, Volume 270, 2025, 155975, ISSN 0344-0338. /[3]Reichl, K. D., et al., Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023. Expert Opinion on Therapeutic Patents, 34(3), 159–169./[4]Centore, R.C. et al. (2023) Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers.
CAS Number: 2368903-18-6
Molecular Weight: 555.69
Compound Purity: 98.41
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL
Target: Epigenetic Reader Domain
English
Deutsch
